Gabriela Anahi Rozic

Dr. Gabriela Anahi Rozic

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ISIrit Shapira-Netanelov
Irit Shapira-Netanelov
OFOlga Furman
Olga Furman
D(Dikla Rogachevsky (Yitzhakie)
Dikla Rogachevsky (Yitzhakie)
GLGalia Luboshits
Galia Luboshits
YMYael Maizels
Yael Maizels
GRGabriela Anahi Rozic
Gabriela Anahi Rozic
Background/Purpose: Conventional three-dimensional in vitro tumor models often fail to fully capture the complexity of the tumor microenvironment, particularly the diverse populations of cancer-associated fibroblasts that contribute to poor prognosis and treatment resistance. The purpose of this study is to develop a patient-specific gastric cancer assembloid model that integrates tumor epithelial cells with matched stromal cell subtypes, each derived using tailored growth media to enhance cancer preclinical research and advance personalized therapeutic strategies. Methods: Tumor tissue was dissociated, and cells expanded in media for organoids, mesenchymal stem cells, fibroblasts, or endothelial cells. The resulting tumor-derived subpopulations were co-cultured in an optimized assembloid medium supporting each cell type’s growth. Biomarker expression was assessed by immunofluorescence staining, and transcriptomic profiles were analyzed by RNA sequencing. Drug responsiveness was evaluated using cell viability assays following treatment with various therapeutic agents. Results: The optimized co-culture conditions yielded assembloids that closely mimicked the cellular heterogeneity of primary tumors, confirmed by the expression of epithelial and stromal markers. Compared to monocultures, the assembloids showed higher expression of inflammatory cytokines, extracellular matrix remodeling factors, and tumor progression-related genes across different organoids and stromal ratios. Drug screening revealed patient- and drug-specific variability. While some drugs were effective in both organoid and assembloid models, others lost efficacy in the assembloids, highlighting the critical role of stromal components in modulating drug responses. Conclusions: This assembloid system offers a robust platform to study tumor–stroma interactions, identify resistance mechanisms, and accelerate drug discovery and personalized therapeutic strategies for gastric cancer.

31 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
GRGabriela Anahi Rozic
Gabriela Anahi Rozic
LPLena Paukov
Lena Paukov
ZCZiv Cohen
Ziv Cohen
ISIrit Shapira
Irit Shapira
ADAdrian Duek
Adrian Duek
MLMerav Leiba
Merav Leiba
STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models

1 January 2025 in American Journal of Cancer Research
Verified
Journal Article
Closed access
GRGabriela Anahi Rozic
Gabriela Anahi Rozic
YMYaara Makaros
Yaara Makaros
ISIrit Shapira-Netanelov
Irit Shapira-Netanelov
TKTatiana Kardash
Tatiana Kardash
YMYael Maizels
Yael Maizels
ADAdrian Duek
Adrian Duek
Myeloproliferative neoplasms are clonal hematopoietic disorders characterized by excessive mature blood cells production, dysregulated JAK-STAT signaling, and increased angiogenesis. Current therapies, such as ruxolitinib, improve symptoms but lack disease-modifying effects. This study aimed to evaluate the cytotoxic and mechanistic effects of STK405759, a fully synthetic microtubule targeting agent in myeloproliferative neoplasms models. Three representative myeloproliferative neoplasms cell lines (HEL, SET-2, MEG-01) were treated with STK405759 as a single agent or in combination with ruxolitinib. Cytotoxicity was evaluated by XTT assays, apoptosis via Annexin V/propidium iodide staining, and cell cycle distribution by flow cytometry. Microtubule dynamics were examined by immunoblotting and immunofluorescence. Apoptosis-related proteins, cytokine secretion and JAK-STAT pathway activation were analyzed using antibody arrays. STK405759 showed potent cytotoxicity in JAK2 V617F-positive HEL and SET-2 cells and BCR-ABL1-positive MEG-01 cells. Combination with ruxolitinib yielded synergistic effects in HEL and SET-2 cells. Mechanistically, STK405759 disrupted microtubule organization, reduced α- and β-tubulin polymerization and acetylated α-tubulin, leading to G2/M arrest and apoptosis. In SET-2 cells, STK405759 significantly increased STAT1 phosphorylation while causing its retention in the cytoplasm. Treatment also decreased VEGF secretion in both monocultures and HS-5 stromal co-cultures and induced IL-1β in co-cultures. These findings demonstrate that STK405759 exerts potent cytotoxic activity, disrupts microtubules, modulates STAT1 signaling, reduces VEGF secretion, and induces a distinct cytokine profile, while synergizing with ruxolitinib, supporting its further preclinical development as a potential therapeutic strategy in myeloproliferative neoplasms.